GNE-9815 (compound 7) is a highly selective, orally bioavailable pan-RAF inhibitor. For CRAF and BRAF, respectively, GNE-9815 displays Ki values of 0.062 and 0.19 nM. The MAPK pathway is modulated synergistically when GNE-9815 and the MEK inhibitor Cobimetinib are combined. Cancers with the KRAS mutation can be studied using GNE-9815.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.